Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.

Adv Ther · 2023 · PMC10427520 · PMID 37368103

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

This study showed that a greater proportion of RZB-treated patients achieved endoscopic response, with an overall trend toward endoscopic remission, than UST-treated patients.

also in 1,952 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.